Neuromuscular Complications of Systemic Amyloidosis

Am J Med. 2022 Apr:135 Suppl 1:S13-S19. doi: 10.1016/j.amjmed.2022.01.006. Epub 2022 Jan 31.

Abstract

Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues, frequently at a distance from the site of synthesis. The 2 most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy. Diagnosis can be challenging, and abundant suspicion is required to identify patients. As neurological manifestations of amyloidosis may precede involvement of other organs by several years, recognizing amyloid neuropathy and myopathy are crucial, especially in this new and exciting era of effective therapies for AL and ATTR neuropathy. This review will focus on the neuromuscular manifestations of AL and ATTR amyloidosis, diagnostic approaches, and recent advances in the treatment of amyloid neuropathy.

Keywords: Familial amyloid peripheral neuropathy; Light-chain; Myopathy; Transthyretin.

Publication types

  • Review

MeSH terms

  • Amyloid Neuropathies* / complications
  • Amyloid Neuropathies, Familial* / complications
  • Amyloid Neuropathies, Familial* / diagnosis
  • Amyloid Neuropathies, Familial* / therapy
  • Humans
  • Muscular Diseases*
  • Prealbumin

Substances

  • Prealbumin